You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.


First patient enrolled and treated in Kedrion’s CARES10 clinical study

Kedrion Biopharma announces that it has commenced patient enrollment in its new CARES10 (Clinical Assessment of phaRmacokinetics, Efficacy, Safety of a 10% Ig) clinical study.

CARES10 is a US/CANADA-based open label multicenter phase 3 clinical study to assess efficacy, safety and pharmacokinetics of a 10% intravenous Immunoglobulin (KIg10) in the treatment of adult patients with Primary Immunodeficiency Diseases (PID).

The first patient was screened on April 30th, 2019 and has been receiving treatment since May 10th. In line with the plan, seventeen patients have been enrolled so far. Enrollments will continue until January 2020 with the goal of reaching a total of around 50 patients. The study is scheduled to be completed by Q2 2021.

For more information please contact: